untitled h1
references

1. Marie E. Robert, Mark Skacel, Thomas Ullman, Charles N. Bernstein, Kirk Easley, John R.  
Goldblum. Patterns of Colonic Involvement at Initial Presentation in Ulcerative Colitis Am J Clin Pathol 2004; 122:94-99 2. Siew C Ng, Hai Yun Shi, et al. The Lancet 2017 390, 2769-2778DOI: (10.1016/S01406736(17)32448-0)
3. Loftus EV JrUpdate on the Incidence and Prevalence of Inflammatory Bowel Disease in the United States. Gastroenterol Hepatol. 2016 Nov;12(11):704-707.  
4. Imuran (azathioprine). In: Prometheus Laboratories I, ed. *accessdata.fda.gov*. San Diego, California.May 2011.  
5. Purinethol (mercaptopurine). In: DSM Pharmaceuticals I, ed. *accessdata.fda.gov*. Greenville, North Carolina.April 2011.  
6. Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2017 Jan;45(1):3-13. doi: 10.1111/apt.13847.  
7. Remicade (infliximab). In: Janssen Biotech I, ed. accessdata.fda.gov. Horsham, Pennsylvania 2013.  
8. Cimzia (certolizumab pegol). In: UCB I, ed. accessdata.fda.gov. Smyrna, Georgia.September 2013.  
9. Humira (adalimumab). In: AbbVie I, ed. accessdata.fda.gov. North Chicago, Illinois.January 2013.  
10. Asher Kornbluth, MD1, David B. Sachar, MD, MACG1 and The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative Colitis in Adults Am J Gastroenterol 2010; 105:501–523 11. Jostins L, Ripke S, Weersma RK, et al. (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature.*http://doi.org/10.1038/nature11582 12. Gut microbiota in the pathogenesis of inflammatory bowel disease. Atsushi Nishida, Ryo Inoue, Osamu Inatomi, Shigeki Bamba, Yuji Naito, Akira Andoh Clinical Journal of Gastroenterology 2018, 11 (1): 1-10 13. Jeon SR, Chai J, Kim C, Lee CH Current Evidence for the Management of Inflammatory Bowel Diseases Using Fecal Microbiota Transplantation. Current Infectious Disease Reports 2018 May 26, 20 (8): 21 14. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. Jan 2013;368(5):407-415.  
15. Noortje G. Rossen, Susana Fuentes, Mirjam J. van der Spek, Jan G. Tijssen, Jorn H. A. Hartman, Ann Duflou, Mark Löwenberg, Gijs R. van den Brink, Elisabeth M. H. Mathus-Vliegen, Willem M.  
de Vos, Erwin G. Zoetendal, Geert R. D'Haens, and Cyriel Y. Ponsioen. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis Gastroenterology 2015;149:110–118 16. Paul Moayyedi, Michael G. Surette, Peter T. Kim, Josie Libertucci, Melanie Wolfe, Catherine Onischi, David Armstrong, John K. Marshall, Zain Kassam, Walter Reinisch, and Christine H. Lee.  
Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial Gastroenterology 2015;149:102–109 17. Paramsothy S, Paramsothy R, Rubin DT, Kamm MA, Kaakoush NO, Mitchell HM, CastañoRodríguez N. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2017 Oct 1;11(10):1180-1199 18. Vinita Jacob, Carl Crawford, Shirley Cohen-Mekelburg, Monica Viladomiu, Gregory G. Putzel, Yecheskel Schneider, Fatiha Chabouni, Sarah O'Neil, Brian Bosworth, Viola Woo, Nadim J. Ajami, Joseph F. Petrosino, Ylaine Gerardin, Zain Kassam, Mark Smith, Iliyan D. Iliev, Gregory F.  
Sonnenberg, David Artis, Ellen Scherl, Randy S. Longman; Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis, Inflammatory Bowel *Diseases*, Volume 23, Issue 6, 1 June 2017, Pages 903–911 19. João P.B. Silva, Kely C. Navegantes-Lima, Ana L.B. Oliveira, Dávila V.S. Rodrigues, Sílvia L.F.  
Gaspar, Valter V.S. Monteiro, Davi P. Moura and Marta C. Monteiro*, "Protective Mechanisms of Butyrate on Inflammatory Bowel Disease", Current Pharmaceutical Design (2018) 24: 4154 20. Bach Knudsen, K.E.; Lærke, H.N.; Hedemann, M.S.; Nielsen, T.S.; Ingerslev, A.K.; Gundelund Nielsen, D.S.; Theil, P.K.; Purup, S.; Hald, S.; Schioldan, A.G.; Marco, M.L.; Gregersen, S.; Hermansen, K. Impact of Diet-Modulated Butyrate Production on Intestinal Barrier Function and Inflammation. *Nutrients* 2018, 10, 1499.  
21. Arpaia N, Campbell C, Fan X et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504: 451–455.  
22. Furusawa Y, Obata Y, Fukuda S et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446–450.  
23. S.R. Llewellyn, G.J. Britton, E.J. Contijoch, O.H. Vennaro, A. Mortha, J.F. Colombel, A. Grinspan, J.C. Clemente, M. Merad, J.J. Faith. Interactions between diet and the intestinal microbiota alter intestinal permeability and colitis severity in mice. Gastroenterology. 2017 Nov 23. pii: S00165085(17)36388-6. doi: 10.1053/j.gastro.2017.11.030 24. Ana Letícia Malheiros Silveira, Adaliene Versiani Matos Ferreira, et al. Preventive rather than therapeutic treatment with high fiber diet attenuates clinical and inflammatory markers of acute and chronic DSS-induced colitis in mice European Journal of Nutrition 2017, 56 (1): 179-191 25. Sonnenburg E.D., Zheng H., Joglekar P., et al: Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microbiota alterations. Cell 2010; 141: pp. 12411252 26. K. Khan, E. Jovanovski, H.V.T. Ho, A.C.R.Marques, A. Zurbau, S.B. Mejia, J.L.Sievenpiper, V. Vuksa n. The effect of viscous soluble fiber on blood pressure: A systematic review and meta-analysis of randomized controlled trials. *Nutrition, Metabolism and Cardiovascular Diseases*, Volume 28, Issue 1, 2018, pp. 3-13 27. Linda Wedlake, Natalie Slack, H. Jervoise N. Andreyev, Kevin Whelan; Fiber in the Treatment and Maintenance of Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials, Inflammatory Bowel *Diseases*, Volume 20, Issue 3, 1 March 2014, Pages 576586, https://doi.org/10.1097/01.MIB.0000437984.92565.31 28. Llewellyn SR, Britton GJ, Contijoch EJ, Vennaro OH, Mortha A, Colombel JF, Grinspan A, Clemente JC, Merad M, and Faith JJ. Interactions Between Diet and the Intestinal Microbiota Alter Intestinal Permeability and Colitis Severity in Mice. *Gastroenterology.* 2018;154(4):1037-46 e2.  
29. Chen L, He Z, Iuga AC, Martins Filho SN, Faith JJ, Clemente JC, Deshpande M, Jayaprakash A,
Colombel JF, Lafaille JJ, et al. Diet Modifies Colonic Microbiota and CD4(+) T-Cell Repertoire to Induce Flares of Colitis in Mice With Myeloid-Cell Expression of Interleukin 23. *Gastroenterology.*
2018;155(4):1177-91 e16.  
30. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. Dec 2005;353(23):2462-2476.  
31. Rosner B. *Fundamentals of Biostatistics*. 7th ed. Boston, MA: Brooks/Cole; 2011. 32. Wong, C., Harris, P. J., & Ferguson, L. R. (2016). Potential Benefits of Dietary Fibre Intervention in Inflammatory Bowel Disease. *International journal of molecular sciences,* 17(6), 919.  
doi:10.3390/ijms17060919 33. U.S. Food and Drug Administration (FDA, 2016). "Memorandum to the File: Scientific Review of the Beneficial Physiological Effects of Non-Digestible Carbohydrates for Meeting the FDA
Definition of Dietary Fiber," 2016.  
34. P, Editor(s): Ronald I. Shorr, Angela B. Hoth, Nathan Rawls, Drugs for the Geriatric Patient, W.B.  
Saunders, 2007, Pages 930-1062. ISBN 9781416002086. https://doi.org/10.1016/B978141600208-6.50019-X.